Dacomitinib Tablets

Function and indication:
Single-agent is used for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion mutation or exon 21 L858R substitution mutation.
Usage and Dosage:
Patient Selection: Dacotinib tablets should be used in medical institutions with experience in use and under the guidance of specific professional technicians. It must be used for patients who are confirmed to be positive for EGFR exon 19 deletion mutation or exon 21 L858R substitution mutation based on tumor samples with fully validated detection methods. Recommended dose: The recommended dose of this product is 45 mg orally once a day until disease progression or unacceptable toxicity occurs. This product can be taken with or without food (see [Pharmacokinetics]). Take this product at approximately the same time every day. If the patient vomits or misses a dose, the missed dose should not be added or supplemented, but the prescribed dose should be taken at the next dose time.
Adverse reactions:
The following adverse drug reactions are described elsewhere in this manual: interstitial lung disease (see [Precautions]), diarrhea (see [Precautions]), skin adverse reactions (see [Precautions]).
Contraindications:
None.